ProMIS Neurosciences (PMN) Competitors

Cardiol Therapeutics (NASDAQ:CRDL) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.

Which has better valuation & earnings, CRDL or PMN?

ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$20.84M	-$0.39	-3.08
ProMIS Neurosciences	N/A	N/A	-$13.21M	-$0.10	-8.15

Does the MarketBeat Community prefer CRDL or PMN?

Cardiol Therapeutics received 24 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 65.00% of users gave Cardiol Therapeutics an outperform vote.

Company	Underperform	Outperform
Cardiol Therapeutics	Outperform Votes 26 65.00%	Underperform Votes 14 35.00%
ProMIS Neurosciences	Outperform Votes 2 100.00%	Underperform Votes No Votes

Does the media refer more to CRDL or PMN?

In the previous week, Cardiol Therapeutics had 3 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 5 mentions for Cardiol Therapeutics and 2 mentions for ProMIS Neurosciences. Cardiol Therapeutics' average media sentiment score of 0.88 beat ProMIS Neurosciences' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProMIS Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of CRDL or PMN?

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 4.4% of ProMIS Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is CRDL or PMN more profitable?

Cardiol Therapeutics' return on equity of -194.40% beat ProMIS Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-194.40%	-129.07%
ProMIS Neurosciences	N/A	-636.20%	-130.32%

Do analysts recommend CRDL or PMN?

Cardiol Therapeutics currently has a consensus price target of $8.40, suggesting a potential upside of 600.00%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than ProMIS Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29
ProMIS Neurosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more risk & volatility, CRDL or PMN?

Cardiol Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Summary

Cardiol Therapeutics beats ProMIS Neurosciences on 12 of the 16 factors compared between the two stocks.